Clinical Trial

A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 24, 2025 (before its estimated July 3, 2026 completion). Its status may not reflect the trial's current state.
Summary
This was an open-label, randomized, fasting, single-dose, 2-sequence, 2-period crossover study to evaluate the pharmacokinetics and safety between single oral administration of "BR3006" and co-administration of "BR3006A", "BR3006B," and "BR3006C" in healthy adult volunteers.
Trial Details
NCT Number NCT07083388
Lead Sponsor Boryung Pharmaceutical Co., Ltd
Conditions Diabetes Mellitus
Enrollment 52 participants
Start Date 2025-07-03
Primary Completion 2026-07-03 (estimated)
Study Completion 2026-07-03 (estimated)
Updated on ClinicalTrials.gov 2025-07-24